Hyperthermic intraperitoneal chemotherapy is an independent risk factor for development of acute kidney injury

Dagel T., Misirlioglu S., Tanju S., AFŞAR B., Selcukbiriciks F., Erus S., ...More

JOURNAL OF BUON, vol.23, no.5, pp.1528-1533, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 5
  • Publication Date: 2018
  • Journal Name: JOURNAL OF BUON
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1528-1533
  • Süleyman Demirel University Affiliated: Yes


Purpose: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) or hyperthermic intrapleural chemotherapy (HIC) has been established as the new treatment modality for selected patients with peritoneal and pleural malignancies. The purpose of the study was to compare the development of acute kidney injury (AKI) in patients who received intravenous cisplatin alone, HIPEC and underwent surgery.